Related Experiment Video
Updated: Jun 15, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe
Ana Lucia de Almeida Kater1, Marcelo Costa Batista, Sandra Roberta Gouvea Ferreira
1Division of Endocrinology, Department of Internal Medicine, Federal University of São Paulo, São Paulo 04023-062, Brazil.
Metabolism: Clinical and Experimental
|March 5, 2010
Summary
Simvastatin improved endothelial function in prediabetic individuals, while ezetimibe showed potential negative effects. Combination therapy did not alter insulin sensitivity but reduced inflammatory markers.
Area of Science:
- Cardiovascular Pharmacology
- Endocrinology
- Metabolic Syndrome
Background:
- Lipid-lowering agents may impact cardiovascular events via non-lipid risk factors like insulin resistance and inflammation.
- Ezetimibe inhibits cholesterol absorption; statins reduce cholesterol synthesis.
- The pleiotropic effects of combining ezetimibe with statins on atherosclerosis are not fully understood.
Purpose of the Study:
- To assess the effects of simvastatin and ezetimibe, alone and in combination, on endothelial function and insulin sensitivity in prediabetic subjects.
- To investigate potential benefits beyond lipid reduction in slowing the atherosclerotic process.
Main Methods:
- Fifty prediabetic subjects with hypercholesterolemia received ezetimibe or simvastatin monotherapy for 12 weeks, followed by combination therapy for 12 weeks.
- Clinical and laboratory parameters, including markers of endothelial function and insulin sensitivity, were measured at baseline, 12, and 24 weeks.
- Insulin resistance was assessed using the Homeostasis Model Assessment (HOMA-IR) index and insulin area under the curve (AUC).
Main Results:
- Both monotherapies and combination therapy significantly reduced total cholesterol, LDL-C, apolipoprotein B, and triglycerides.
- Simvastatin monotherapy lowered plasminogen activator inhibitor-1 and urinary albumin excretion compared to ezetimibe.
- Combination therapy significantly reduced E-selectin and intravascular cellular adhesion molecule-1, independent of LDL-C changes; no changes in insulin sensitivity markers were observed.
Conclusions:
- Simvastatin appears beneficial for preserving endothelial function in prediabetic individuals with hypercholesterolemia.
- Ezetimibe may have a detrimental effect on endothelial function, indicated by increased adhesion molecule levels.
- Neither simvastatin nor ezetimibe, alone or combined, impacts insulin sensitivity in this population.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...